“Global Magnetic Resonance Imaging (MRI) systems market set to grow to $9.9bn by 2024” says new Visiongain report

08 January 2019
Pharma

Visiongain has launched a new pharma report Global Magnetic Resonance Imaging (MRI) Systems Market Forecast 2019-2029: High-Field MRI, Ultra-High Field MRI, Low-Field MRI.

Rapid expansions in the applications of MRI and an increased medical awareness of MRI systems as a diagnostic tool have triggered strong growth in this market in recent years. As this trend continues, and new applications are discovered (coupled with continued product innovation), the market will continue to achieve strong revenue growth. The future of the MRI devices market look promising, as more innovative devices are in the R&D pipeline and eventually enters the market. In the recent years, there have been progressive improvements in the safety, comfort, convince and efficacy of MRI devices, yet there is potential for more innovation. With steady progression of the industry, MRI equipment will gain popularity among healthcare providers, with that market expanding worldwide and the devices developed to address a wider range of medical conditions. As MRI markets in developed countries mature, emerging national markets will continue to drive the growth of MRI sales, as a result of increased healthcare spending.

The lead analyst of the report commented "Opportunities in the market include the development and increased preference towards ultra-high field systems which are capable of imaging ions and neurotransmitters, ultimately achieving a new level of diagnostic imaging.

There are strong opportunities for market growth in rising countries such as China and India where the density of MRI scanners per million of the population is a major concern. As the global awareness of the benefits of MRI increases, and in response to strong patient demand, government spending in healthcare in these respective countries is expected to increase. This will ultimately provide strong opportunities for market players to direct their focus towards emerging countries, rather than in developed countries, where the MRI market is steadily reaching saturation."

Leading companies featured in the report include Aurora Healthcare US Corp, Bruker Corporation, Canon Medical Systems, Esaote SpA, GE Healthcare, Hitachi, Ltd., Neusoft Medical Systems Co., Ltd., Philips Healthcare, Shenzhen Anke High-tech Co., Ltd., Siemens Healthineers

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

Read

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

Read

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

Read

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever